Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment

Experimental and Molecular Pathology

Volumn 95, Issue 2, 2013, Pages 174-179

  Green, Taryn L ^a   Cruse, Julius M ^a   Lewis, Robert E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Circulating tumor cell; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE SYSTEM; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; TUMOR CELL;

CIRCULATING TUMOR CELL; METASTATIC BREAST CANCER;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; KILLER CELLS, NATURAL; NEOPLASTIC CELLS, CIRCULATING; RADIOIMMUNOASSAY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880689844     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.06.013     Document Type: Article

References (40)

1. Alemar J., Schuur E.R. Progress in using circulating tumor cell information to improve metastatic breast cancer therapy. J. Oncol. 2013, 1-8. (Article ID 702732).
2. Allard W.J., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10:6897-6904.
3. Basith S., et al. Roles of Toll-like receptors in cancer: a double-edged sword for defense and offense. Arch. Pharmacal Res. 2012, 35:1297-1316.
4. Bhattacharya D., Yusuf N. Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int. J. Breast Cancer 2012, 1-6. (Article ID 716564).
5. Bidard F.C., et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 2010, 21:729-733.
6. Chekhun V.F. Stroma - regulator of cancer cell progression. Exp. Oncol. 2009, 31:126.
7. Cristofanilli M., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
8. Cruse J.M., et al. Immunology Guidebook 2004, Elsevier, Amsterdam.
9. de Visser K.E., Coussens L.M. The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol. Immunother. 2005, 54:1143-1152.
10. DeNardo D.G., et al. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008, 27:11-18.
11. Dunn G.P., et al. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
12. Fan J., Malik A.B. Toll-like receptor-4 (TLR4) signaling augments chemokines-induced neutrophil migration by modulating cell surface expression of chemokines receptors. Nat. Med. 2003, 9:315-321.
13. Fehm T., et al. Determination of HER2 status using both serum HER2 levels and circulating tumors cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007, 9:R74.
14. Fiegl H., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005, 65:1141-1145.
15. Glynn S.A., et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J. Clin. Investig. 2010, 120:3843-3854.
16. Gonzalez L.O., et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br. J. Cancer 2007, 97:957-963.
17. Gonzalez-Reyes S., et al. Study of TLR3, TLR4, and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010, 10:665.
18. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
19. Harmey J.H., et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer 2002, 101:415-422.
20. Huang B., et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
21. Ignatiadis M., et al. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011, 6:e15624.
22. Igney F.H., Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukocyte Biol. 2002, 71:907-920.
23. Karin M., et al. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-825.
24. Kelly M.G., et al. TLR4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006, 66:3859-3868.
25. Kluwe J., et al. Toll-like receptors, wound healing, and carcinogenesis. J. Mol. Med. 2009, 87:125-138.
26. Li X., et al. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010, 49:1-9.
27. Lianidou E., Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem. 2011, 57:1242-1255.
28. Liao S.J., et al. Triggering of toll-like receptor 4 on metastatic breast cancer cells promotes alpha v beta 3 -mediated adhesion and invasive migration. Breast Cancer Res. Treat. 2012, 133:853-863.
29. Montag A., Kumar V. The Female Genital System and Breast. Robbins Basic Pathology 2007, 711-750. Elsevier, Philadelphia, PA. V. Kumar (Ed.).
30. Nadal R., et al. Biomarkers characterization of circulating tumor cells in breast cancer patients. Breast Cancer Research 2012, 14:R71.
31. Nakanishi C., Toi M. Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
32. Patel N., Sauter E.R. Body fluid micro(mi) RNAs as biomarkers for human cancer. J. Nucleic Acids Investig. 2011, 2:1-4.
33. Ridnour L.A., et al. Molecular pathways: toll-like receptors in the tumor microenvironment - poor prognosis or new therapeutic opportunity. Clin. Cancer Res. 2013, 19:1340-1346.
34. So E.Y., Ouchi T. The application of toll-like receptors for cancer therapy. Int. J. Biol. Sci. 2010, 6:675-681.
35. Swaby R.F., Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med. 2011, 9:1-7.
36. Theodoropoulos G.E., et al. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast 2012, 21:534-538.
37. Tibbe A.G., et al. Statistical considerations for enumeration of circulating tumor cells. Cytometry 2007, 71:154-162.
38. Yang H., et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J. Exp. Clin. Cancer Res. 2010, 29:92.
39. Zhang L., et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 2012, 18:5701-5710.
40. Zitvogel L., et al. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8:59-73.